El interés en corto de Liberty Media da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Liberty Media. Los datos de interés en corto se actualizan cada dos semanas.

Liberty Media (NASDAQ:FWONA) Bolsa, Informe de interés en corto

Liberty Formula One Gr

Liberty Media

Liberty Formula One Group

Liberty Media Corp along with its subsidiaries is engaged in the media and entertainment industries in North America and the United Kingdom. The company owns interests in a high-quality portfolio of assets across the media, entertainment and sports industries. The company derives its maximum revenue from United Kingdom.

The,Apple,Tv,App,Shows,The,Ted,Lasso,Series,On

Entertainment

Sports

Trading Ideas

AAPL

FWONA

FWONK

Apple TV+ trae de vuelta a Ted Lasso y refuerza su apuesta deportiva con MLB, MLS y la F1 para atraer suscriptores.

Apple TV+ recupera a Ted Lasso y acelera su apuesta por el deporte

Abacus Global Management, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABL#NASDAQ">ABL</a>) ("Abacus" or the "Company"), a leader in the alternative asset management space, today announced the expiration and results of its previously announced exchange offer (the "Offer") and consent solicitation (the "Consent Solicitation") relating to its (i) outstanding public warrants (the "public warrants") and (ii) outstanding private placement warrants (the "private placement warrants" and, together with the public warrants, the "warrants") to purchase shares of common stock, par value $0.0001 per share, of the Company ("common stock"). The Offer and Consent Solicitation expired at 11:59 p.m., Eastern Time, on July 29, 2025.
The Company has been advised that 18,188,277 warrants (including 500 warrants tendered through guaranteed delivery), or approximately 88% of the outstanding warrants, were validly tendered and not validly withdrawn prior to the expiration of the Offer and Consent Solicitation. The Company expects to accept all validly tendered warrants for exchange and settlement on or before July 30, 2025. In addition, pursuant to the Consent Solicitation, the Company received the approval of parties representing approximately 83% of the outstanding public warrants and approximately 94% of the outstanding private placement warrants to amend the warrant agreement that governs the warrants (such amendment, the "Warrant Amendment"), which exceeds the threshold of 50% of the outstanding public warrants required to effect the Warrant Amendment. Accordingly, the Company and Continental Stock Transfer &amp; Trust Company entered into the Warrant Amendment, dated July 30, 2025, and the Company expects to&nbsp;exercise its right, in accordance with the terms of the Warrant Amendment, to exchange each warrant that is outstanding upon the closing of the Offer for 0.207 shares of common stock per warrant, which is a ratio 10% less than the exchange ratio applicable to the Offer (the "Post-Offer Exchange").
The Company engaged SG Americas Securities, LLC as the dealer manager for the Offer and Consent Solicitation, D.F. King &amp; Co., Inc. as the information agent for the Offer and Consent Solicitation, and Continental Stock Transfer &amp; Trust Company served as the exchange agent for the Offer and Consent Solicitation.

News

Offerings

Abacus Global Management Announces 88% Warrant Exchange Participation, Moves Forward With Warrant Amendment And Post-Offer Exchange

New direct bank-to-wallet link, Chase Ultimate Rewards transfer, and the ability to use Chase credit cards, will give users more ways than ever to get into crypto
Today, JPMorganChase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) and Coinbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) announced a strategic partnership that sets a new standard for customer choice and security in the innovation economy. This collaboration introduces features designed to enhance access and optionality for our mutual customers.
The initial phase of the partnership includes new features for mutual customers, including:
<ul>
<li>Direct Bank-to-Wallet Connection: Through JPMorgan's secure API, Chase customers will be able to seamlessly link their bank accounts to Coinbase wallets. This direct connection will help mutual customers transact with the confidence, security, and privacy they're used to as customers of Chase.</li>
<li>Transfer of Chase Ultimate Rewards Points: Chase customers will be able to transfer their Chase Ultimate Rewards points to their Coinbase Account at one-to-one redemption ratio (100 points equals $1.00 in redemption value). This marks the first time a major credit card rewards program will be used to fund a crypto wallet.</li>
<li>Beginning this Fall, the ability to use Chase credit cards on Coinbase: For the first time,customers will have the ability to fund their Coinbase accounts using Chase credit cards.</li>
</ul>
We expect these direct bank-to-wallet and Ultimate Rewards features to go live in 2026, and the ability to use credit cards to fund a Coinbase account in Fall 2025.

COIN

JPMorgan And Coinbase Partner To Launch Direct Bank-To-Wallet Transfers, Chase Rewards-To-Crypto Conversions, And Credit Card Funding

<a href="https://www.statnews.com/2025/07/30/new-amsterdam-pharma-cholesterol-drug-alzheimers/" title="https://www.statnews.com/2025/07/30/new-amsterdam-pharma-cholesterol-drug-alzheimers/">https://www.statnews.com/2025/07/30/new-amsterdam-pharma-cholesterol-drug-alzheimers/</a>

Biotech

General

NAMS

'Biotech Says Its Cholesterol Drug Shows Signs Of Preventing Alzheimer's; NewAmsterdam Pharma Hopes Medicine Born Out Of Big Failures May Have An Unexpected Benefit' - STAT News

DA Davidson analyst Rudy Kessinger maintains CommVault Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVLT#NASDAQ">CVLT</a>) with a Buy and raises the price target from $200 to $220.

Price Target

Analyst Ratings

CVLT

DA Davidson Maintains Buy on CommVault Systems, Raises Price Target to $220

IXHL

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

DA Davidson analyst Rudy Kessinger maintains Varonis Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNS#NASDAQ">VRNS</a>) with a Neutral and raises the price target from $47 to $50.

VRNS

DA Davidson Maintains Neutral on Varonis Systems, Raises Price Target to $50

<a href="https://www.wsj.com/business/media/amazon-to-pay-new-york-times-at-least-20-million-a-year-in-ai-deal-66db8503" title="https://www.wsj.com/business/media/amazon-to-pay-new-york-times-at-least-20-million-a-year-in-ai-deal-66db8503">https://www.wsj.com/business/media/amazon-to-pay-new-york-times-at-least-20-million-a-year-in-ai-deal-66db8503</a>

AMZN

'Amazon To Pay New York Times At Least $20 Million A Year In AI Deal; The Multiyear Deal Lets Amazon Use Content From The Times's News And Cooking Sections And The Athletic' - WSJ

Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XGN#NASDAQ">XGN</a>) with a Buy and raises the price target from $8 to $11.

Canaccord Genuity Maintains Buy on Exagen, Raises Price Target to $11

CyberArk Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) reported quarterly earnings of $0.88 per share which beat the analyst consensus estimate of $0.80 by 10.41 percent. This is a 62.96 percent increase over earnings of $0.54 per share from the same period last year. The company reported quarterly sales of $328.000 million which beat the analyst consensus estimate of $316.088 million by 3.77 percent. This is a 45.97 percent increase over sales of $224.706 million the same period last year.

Earnings

Earnings Beats

CYBR

CyberArk Software Q2 Adj. EPS $0.88 Beats $0.80 Estimate, Sales $328M Beat $316.088M Estimate

Guidance

TEVA

During Conf Call, Teva Pharmaceutical CFO Reportedly Says Confirmed U.S. Tariffs Are Absorbed Into 2025 Non-GAAP Outlook

Etsy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) reported quarterly sales of $672.663 million which beat the analyst consensus estimate of $646.534 million by 4.04 percent. This is a 3.84 percent increase over sales of $647.806 million the same period last year.

Earnings Misses

ETSY

CORRECTION: Etsy Q2 Sales $672.663M Beat $646.534M Estimate

Susquehanna analyst Bascome Majors maintains Werner Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WERN#NASDAQ">WERN</a>) with a Neutral and raises the price target from $25 to $27.

WERN

Susquehanna Maintains Neutral on Werner Enterprises, Raises Price Target to $27

ANIX

Anixa Biosciences Issued Notice Of Allowance Bt Canadian Intellectual Property Office For A Patent Related To Its Breast Cancer Vaccine Technology

Susquehanna analyst Shyam Patil maintains Varonis Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNS#NASDAQ">VRNS</a>) with a Positive and raises the price target from $55 to $65.

Susquehanna Maintains Positive on Varonis Systems, Raises Price Target to $65

Susquehanna analyst Bascome Majors maintains United Parcel Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) with a Neutral and lowers the price target from $110 to $100.

Susquehanna Maintains Neutral on United Parcel Service, Lowers Price Target to $100

PANW

Palo Alto Says Transaction Expected To Be Immediately Accretive To Revenue Growth And Gross Margin, Expects Deal To Be Accretive To Free Cash Flow Per Share In 2028 Following The First Full Year Of Realization Of Synergies

Susquehanna analyst Bascome Majors maintains Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) with a Positive and lowers the price target from $260 to $257.

Susquehanna Maintains Positive on Union Pacific, Lowers Price Target to $257

Palo Alto Networks To Acquire CyberArk; CyberArk Shareholders To Receive $45 In Cash And 2.2005 Shares Of Palo Alto Networks For Each Cyberark Share

Newmark Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRK#NASDAQ">NMRK</a>) raises FY2025 Adj EPS guidance from $1.40-$1.50 to $1.47-$1.57 vs $1.43 analyst estimate. Raises FY2025 sales outlook from $2.900 billion-$3.100 billion to $3.050 billion-$3.250 billion vs $3.055 billion estimate.

NMRK

Newmark Group Raises FY2025 Adj EPS Guidance from $1.40-$1.50 to $1.47-$1.57 vs $1.43 Est; Raises FY2025 Sales Guidance from $2.900B-$3.100B to $3.050B-$3.250B vs $3.055B Est

Statistically and clinically significant improvements across key clinical endpoints; IHL-42X reduced AHI by up to 83% from baseline. IHL-42X demonstrates compelling clinical benefit and an outstanding safety profile that exceeded expectations.
NEW YORK and MELBOURNE, Australia, July 30, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IXHL#NASDAQ">IXHL</a>) ("Incannex" or the "Company") is excited to share positive topline results from its RePOSA Phase 2 clinical trial evaluating IHL-42X, a novel oral drug candidate for obstructive sleep apnoea (OSA). With over 900 million people affected globally and no approved oral pharmaceutical treatments currently available, IHL-42X's robust efficacy and exceptional safety profile position it as a potential transformative therapy for OSA patients worldwide. The results confirm statistically significant and clinically meaningful improvements across key endpoints assessed in the study, reinforcing IHL-42x's potential as a best-in-class therapy for patients with OSA.
Compelling Clinical Efficacy The RePOSA Phase 2 trial demonstrated clear statistically and clinically significant improvements across multiple key endpoints for patients receiving IHL-42X compared to placebo, highlighting its potential to reduce OSA severity and enhance patient quality of life:
<ul>
<li>Apnoea-Hypopnoea Index (AHI):&nbsp;The low-dose and high-dose IHL-42X groups achieved a statistically significant reduction in percent change in AHI from baseline compared to placebo (p&lt;0.05), the primary measure of OSA severity. Maximum reductions in AHI were observed at up to 83% for the high-dose group and up to 79% for the low-dose group. Notably, 33.3% of patients in the low-dose group and 41.2% in the high-dose group achieved a greater than 30% reduction in AHI, while 13.9% (low-dose) and 14.7% (high-dose) experienced reductions exceeding 50%—demonstrating a strong therapeutic response in a substantial subset of the population.</li>
<li>Patient Global Impression of Change (PGI-C) Sleep related impairment: The low-dose IHL-42X group showed statistically significant improvement (p&lt;0.05), reflecting meaningful patient-perceived benefits.</li>
<li>PGI-C Fatigue: Statistically significant improvement in the low-dose group, suggesting enhanced daytime alertness and reduced fatigue.</li>
<li>Oxygen Desaturation Index (ODI): Both low- and high-dose groups demonstrated statistically significant improvements, indicating better oxygenation during sleep.</li>
<li>Patient-Reported Outcomes: IHL-42X led to clinically significant improvements in patient-reported outcome measures, including the Functional Outcomes of Sleep Questionnaire-10 (FOSQ-10), PROMIS Sleep-Related Impairment 8a (PROMIS-SRI 8a), PROMIS Fatigue 7a, and Epworth Sleepiness Scale (ESS) in both low- and high-dose groups, demonstrating enhanced sleep quality, reduced daytime fatigue, and improved daily functioning for patients with OSA.</li>
<li>Polysomnography (PSG) Metrics: IHL-42X drastically improved objective sleep parameters as measured by PSG.
<ul>
<li>Wake After Sleep Onset (WASO): Reduced by 29.8% in the high-dose arm, meaning patients spent less time awake during the night.</li>
<li>AHI During Supine Sleep: Decreased by 30.3% in the high-dose arm, a critical improvement given supine sleep exacerbates apneic events.</li>
</ul>
</li>
</ul>
These results collectively demonstrate IHL-42X's ability to address both objective and subjective aspects of OSA, offering compelling clinical benefits to patients.
Outstanding Safety Profile IHL-42X was well tolerated across both low- and high-dose cohorts. No serious adverse events were reported during the treatment period, and treatment-emergent adverse effects (TEAEs) were infrequent, with the majority being mild or moderate in severity. This excellent safety profile supports IHL-42X's potential for broad patient use.

Incannex Reports Phase 2 Results For IHL-42X, Reducing Sleep Apnea Severity By Up To 83% With Strong Safety Profile

Press Releases

Liberty Media Corporation Reports Fourth Quarter and Year End 2024 Financial Results

Liberty Media Corporation Announces First Quarter Earnings Release and Conference Call

Liberty Media Corporation to Present at J.P. Morgan Global Technology, Media and Communications Conference

Liberty Media Corporation Reports First Quarter 2025 Financial Results

Social Media

Disney and Formula 1® Unveil Collaboration with Disney's Mickey & Friends Launching in 2026

The Sound of Speed: Sting Energy®, a PepsiCo Energy Drink, Hits the Track with Formula 1®

European Commission Approves Liberty Media's Acquisition of MotoGP™

Allwyn and Formula 1® celebrate power of community by launching F1® Allwyn Global Community Award

Liberty Media Corporation Completes Acquisition of MotoGP™

Liberty Media Corporation Announces Second Quarter Earnings Release and Conference Call

LLYVA

LLYVK

AMC Entertainment Holdings, Inc. Class A Common Stock

AMC Entertainment Hldgs

Atlanta Braves Holdings, Inc. - Series A Common Stock

Atlanta Braves Holdings

Atlanta Braves Holdings, Inc. - Series C Common Stock

Cinemark Holdings Inc Cinemark Holdings, Inc. Common Stock

Cinemark Holdings

CuriosityStream Inc. - Class A Common Stock

CuriosityStream

Walt Disney

Liberty Media Corporation - Series A Liberty Formula One Common Stock

Ordinary Shares (New Liberty Formula One) Series A

Liberty Media Corporation - Series C Liberty Formula One Common Stock

Ordinary Shares (New Liberty Formula One) Series C

iQIYI

Lionsgate Studios

Liberty Media Corporation - Series A Liberty Live Common Stock

Liberty Live

Ordinary Shares (New Liberty Live) Series A

Liberty Media Corporation - Series C Liberty Live Common Stock

Ordinary Shares (New Liberty Live) Series C

Live Nation Entertainment, Inc. Common Stock

Live Nation Entertainment

Manchester United Ltd. Class A Ordinary Shares

Manchester United

Marcus

Madison Square Garden Entertainment Corp. Class A Common Stock

Madison Square Garden

Madison Square Garden Sports Corp. Class A Common Stock (New)

Netflix

Roku

Reservoir Media

Sphere Entertainment Co. Class A Common Stock

Sphere Entertainment

Starz Entertainment Corp. - Common Shares

Starz Entertainment

TKO Group Holdings, Inc. Class A Common Stock

TKO Group Holdings

Tencent Music Entertainment Group American Depositary Shares, each representing two Class A Ordinary Shares

Comments

Liberty Media

Interés en corto

Liberty Media (NASDAQ:FWONA) Bolsa, Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL